| scholarly article | Q13442814 |
| P50 | author | Hans D. Ochs | Q115437 |
| Gordon J. Freeman | Q27088375 | ||
| Bruce R Blazar | Q62070764 | ||
| P2093 | author name string | David J Rawlings | |
| Baowei Peng | |||
| Carol H Miao | |||
| Peiqing Ye | |||
| P2860 | cites work | ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 | Q22001503 |
| B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production | Q24290870 | ||
| T-cell co-stimulation through B7RP-1 and ICOS | Q28141589 | ||
| B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes | Q28143530 | ||
| ICOS co-stimulatory receptor is essential for T-cell activation and function | Q28187985 | ||
| Induction, binding specificity and function of human ICOS | Q28199765 | ||
| The B7 family revisited | Q28240070 | ||
| Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade | Q28564305 | ||
| ICOS is critical for CD40-mediated antibody class switching | Q28589705 | ||
| ICOS is essential for effective T-helper-cell responses | Q28594859 | ||
| An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells | Q28610420 | ||
| Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors | Q33345019 | ||
| Induction of B7-1 in podocytes is associated with nephrotic syndrome | Q33785088 | ||
| Animal testing of retroviral-mediated gene therapy for factor VIII deficiency | Q33800192 | ||
| Gene therapy for the hemophilias | Q64377524 | ||
| Immune dysfunction associated with graft-versus-host reaction in mice transplanted across minor histocompatibility barriers. I. Depressed antigen-specific antibody responses to bacteriophage phi chi 174 | Q69305555 | ||
| CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway | Q70897771 | ||
| Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells | Q73112924 | ||
| Mechanism of the immune response to human factor VIII in murine hemophilia A | Q73503838 | ||
| Gene therapy in hemophilia: clinical trials update | Q74314910 | ||
| Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation | Q78346763 | ||
| Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10 | Q80785928 | ||
| CD4+ CD25+ regulatory T cells inhibit the maturation but not the initiation of an autoantibody response | Q81245701 | ||
| The ICOS molecule plays a crucial role in the development of mucosal tolerance | Q81512249 | ||
| Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse | Q82097240 | ||
| CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates | Q34433847 | ||
| Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression | Q34615481 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs | Q35109095 | ||
| Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice | Q35621550 | ||
| The role of ICOS and other costimulatory molecules in allergy and asthma | Q35681790 | ||
| Immune implications of gene therapy for hemophilia | Q35760790 | ||
| Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice | Q35849770 | ||
| The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. | Q35880886 | ||
| Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. | Q36007714 | ||
| B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells | Q36362252 | ||
| Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling | Q36371140 | ||
| CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion | Q36399063 | ||
| The contribution of immunology to the rational design of novel antibacterial vaccines | Q36844711 | ||
| Recent advances in immune modulation | Q36990123 | ||
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion | Q38520320 | ||
| Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins | Q40446327 | ||
| Sustained expression of human factor VIII in mice using a parvovirus-based vector. | Q40898214 | ||
| Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. | Q41513260 | ||
| Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 | ||
| Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. | Q42087961 | ||
| Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. | Q42183295 | ||
| The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens | Q42441813 | ||
| Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. | Q42645973 | ||
| Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection | Q43655794 | ||
| Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. | Q44367374 | ||
| Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains | Q45113877 | ||
| Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy | Q45409051 | ||
| Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain | Q45859514 | ||
| Prevention and treatment of factor VIII inhibitors in murine hemophilia A. | Q45865107 | ||
| Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. | Q45866971 | ||
| High-Level Factor VIII Gene ExpressionIn VivoAchieved by Nonviral Liver-Specific Gene Therapy Vectors | Q45868873 | ||
| Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. | Q45869966 | ||
| Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders | Q45873471 | ||
| Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice | Q45876434 | ||
| Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. | Q45877779 | ||
| Proceedings: A more uniform measurement of factor VIII inhibitors | Q45878577 | ||
| Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies | Q45879427 | ||
| Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 | ||
| Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. | Q46499903 | ||
| Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). | Q50782599 | ||
| Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors | Q50895162 | ||
| A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo | Q53542220 | ||
| Regulation of immune and autoimmune responses by ICOS. | Q53912899 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemophilia A | Q2092064 |
| hemophilia | Q134003 | ||
| Coagulation factor VIII | Q410137 | ||
| P304 | page(s) | 1662-1672 | |
| P577 | publication date | 2008-06-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice | |
| P478 | volume | 112 |
| Q37376144 | A cellular viewpoint of anti-FVIII immune response in hemophilia A. |
| Q33923877 | Advancements in gene transfer-based therapy for hemophilia A. |
| Q42209182 | Advances in Overcoming Immune Responses following Hemophilia Gene Therapy. |
| Q27012571 | Animal Models of Hemophilia |
| Q37420500 | Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy |
| Q37382199 | B-cell and T-cell epitopes in anti-factor VIII immune responses |
| Q30491507 | CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice |
| Q36644230 | Evading the immune response upon in vivo gene therapy with viral vectors. |
| Q27027224 | FVIII inhibitors: pathogenesis and avoidance |
| Q37387091 | Factor VIII inhibitors: risk factors and methods for prevention and immune modulation |
| Q35670173 | Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation |
| Q28081911 | Gene therapy for hemophilia |
| Q33775537 | Hepatic gene transfer as a means of tolerance induction to transgene products |
| Q45870660 | Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated |
| Q37803130 | Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells |
| Q35144444 | In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti-factor VIII Immune Responses in Hemophilia A Mice Treated With Factor VIII Plasmid-mediated Gene Therapy |
| Q38574966 | In vivo induction of regulatory T cells for immune tolerance in hemophilia |
| Q39877042 | Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice |
| Q41824863 | Induction of tolerance to factor VIII by transient co-administration with rapamycin. |
| Q45875675 | Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. |
| Q34621690 | Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I |
| Q92619754 | Molecular Mechanisms of Inhibitor Development in Hemophilia |
| Q35348677 | Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells |
| Q58761368 | Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells |
| Q38090391 | Progress toward inducing immunologic tolerance to factor VIII |
| Q42362478 | Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells |
| Q27321626 | Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice |
| Q37561470 | Role of regulatory T cells in tolerance to coagulation factors |
| Q47372693 | Route of Antigen Presentation Can Determine the Selection of Foxp3-Dependent or Foxp3-Independent Dominant Immune Tolerance. |
| Q33713999 | Strategies to modulate immune responses: a new frontier for gene therapy |
| Q36479748 | Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine |
| Q51006330 | T regulatory cells participate in the control of germinal centre reactions |
| Q37951935 | Targeting Co-Stimulatory Pathways in Gene Therapy |
| Q42839182 | Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors |
Search more.